全文获取类型
收费全文 | 9283篇 |
免费 | 707篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 124篇 |
儿科学 | 209篇 |
妇产科学 | 256篇 |
基础医学 | 1391篇 |
口腔科学 | 154篇 |
临床医学 | 836篇 |
内科学 | 1984篇 |
皮肤病学 | 118篇 |
神经病学 | 952篇 |
特种医学 | 278篇 |
外科学 | 1358篇 |
综合类 | 135篇 |
现状与发展 | 1篇 |
一般理论 | 14篇 |
预防医学 | 775篇 |
眼科学 | 227篇 |
药学 | 524篇 |
中国医学 | 8篇 |
肿瘤学 | 677篇 |
出版年
2023年 | 99篇 |
2022年 | 181篇 |
2021年 | 304篇 |
2020年 | 176篇 |
2019年 | 305篇 |
2018年 | 319篇 |
2017年 | 194篇 |
2016年 | 209篇 |
2015年 | 257篇 |
2014年 | 322篇 |
2013年 | 461篇 |
2012年 | 582篇 |
2011年 | 655篇 |
2010年 | 308篇 |
2009年 | 316篇 |
2008年 | 488篇 |
2007年 | 555篇 |
2006年 | 463篇 |
2005年 | 507篇 |
2004年 | 511篇 |
2003年 | 446篇 |
2002年 | 434篇 |
2001年 | 97篇 |
2000年 | 107篇 |
1999年 | 111篇 |
1998年 | 86篇 |
1997年 | 81篇 |
1996年 | 65篇 |
1995年 | 71篇 |
1994年 | 69篇 |
1993年 | 57篇 |
1992年 | 54篇 |
1991年 | 47篇 |
1990年 | 51篇 |
1989年 | 66篇 |
1988年 | 51篇 |
1987年 | 63篇 |
1986年 | 44篇 |
1985年 | 33篇 |
1984年 | 47篇 |
1983年 | 44篇 |
1982年 | 43篇 |
1981年 | 37篇 |
1980年 | 32篇 |
1978年 | 33篇 |
1976年 | 33篇 |
1974年 | 37篇 |
1973年 | 37篇 |
1972年 | 34篇 |
1969年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
62.
Treatment of IgA nephropathy 总被引:7,自引:0,他引:7
Julian BA 《Seminars in Nephrology》2000,20(3):277-285
IgA nephropathy (Berger's disease) is the most common primary glomerulonephritis worldwide and was once equated with benign recurrent hematuria. Longer observation showed that 15% to 30% of patients progress to end-stage renal failure after 20 years of clinical manifestations. Because the pathogenesis remains enigmatic, therapy to ameliorate disease progression can not be disease-specific. Several approaches to treatment have generated increasing interest in the last few years, including angiotensin inhibition, glucocorticoids, fish oil, cyclophosphamide, tonsillectomy and mycophenolate mofetil. For patients reaching end-stage renal failure, recurrent disease after transplantation remains a clinically important problem, despite immunosuppression since engraftment. 相似文献
63.
64.
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. 总被引:10,自引:0,他引:10
Yi-He Ling Leonard Liebes Jian-Dong Jiang James F Holland Peter J Elliott Julian Adams Franco M Muggia Roman Perez-Soler 《Clinical cancer research》2003,9(3):1145-1154
PURPOSE: PS-341 is a novel dipeptide boronic acid proteasome inhibitor with in vitro and in vivo antitumor activity that induces mechanisms of apoptosis by unknown mechanisms. EXPERIMENTAL DESIGN: Human non-small cell lung cancer cell lines were used to investigate effects PS-341 on cell proliferation, cell cycle progression, and the induction of apoptosis. RESULTS: PS-341 was 38-360-fold more cytotoxic against H460 cells when compared with the proteasome inhibitors MG-132 and PSI. Differential PS-341 cytotoxic effects were found with respect to P53 function: H322 cells (p53 mutant) were 6-fold less sensitive as compared with H460 cells (p53 wild type); and H358 cells (p53 null) were 1.6-fold more sensitive as compared with H460 cells (p53 wild type). A concentration- and time-dependent cell cycle blockade at G(2)-M phase was seen for H460 cells without any direct effects on microtubule polymerization or depolymerization. PS-341 exposure in H460 cells led to stabilization of p53, induction of p21(cip/waf-1) and MDM2 expression, an increase in cyclin B and cyclin A, and the activation of cyclin B and cyclin A kinases. MDM2 induction was found only in H460 cells, whereas in H322 and H358 cells, G(2)-M-phase arrest, p21(cip/waf-1) induction, and an increase in cyclin B1 were found. The commitment of G(2)-M-phase cells to apoptosis was verified by the activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase in drug-free medium. CONCLUSIONS: Our data suggest that the PS-341-induced G(2)-M-phase arrest may be associated with the inhibition of degradation of cell cycle regulators and that the up-regulation of p21(cip/waf-1) expression may be via p53-dependent and/or -independent pathways. The resulting disturbance of cell cycle progression leads either to growth inhibition or to the initiation of apoptotic pathways. 相似文献
65.
Stereotactic radiosurgery for cavernous malformations 总被引:6,自引:0,他引:6
Pollock BE Garces YI Stafford SL Foote RL Schomberg PJ Link MJ 《Journal of neurosurgery》2000,93(6):987-991
OBJECT: The use of stereotactic radiosurgery to treat cerebral cavernous malformations (CMs) is controversial. To evaluate the efficacy and safety of CM radiosurgery, the authors reviewed the experience at the Mayo Clinic during the past 10 years. METHODS: Seventeen patients underwent radiosurgery for high-surgical-risk CMs in the following sites: thalamus/basal ganglia (four patients), brainstem (12 patients), and corpus callosum (one patient). All patients had experienced at least two documented hemorrhages before undergoing radiosurgery. Stereotactic magnetic resonance (MR) imaging was used for target localization in all cases. The median margin radiation dose was 18 Gy and the median maximum dose was 32 Gy. The median length of follow-up review following radiosurgery was 51 months. The annual hemorrhage rate during the 51 months preceding radiosurgery was 40.1%, compared with 8.8% in the first 2 years following radiosurgery and 2.9% thereafter. In 10 patients (59%) new neurological deficits developed that were associated with regions of increased signal on long-repetition time MR imaging performed a median of 8 months (range 5-16 months) after radiosurgery. Three patients recovered, giving the group a permanent radiation-related morbidity rate of 41%. Compared with 31 patients harboring arteriovenous malformations (AVMs) of sizes and in locations similar to those of the aforementioned CMs, who underwent radiosurgery during the same time period, the patients with CMs were more likely to experience radiation-related complications (any complication, 59% compared with 10%; p < 0.001; permanent complication, 41% compared with 10%; p = 0.02). CONCLUSIONS: It is impossible to conclude that radiosurgery protects patients with CMs against future hemorrhage risk based on the available data, although it appears that some reduction in the bleeding rate occurs after a latency interval of several years. The risk of radiation-related complications after radiosurgery to treat CMs is greater than that found after radiosurgery in AVMs, even when adjusting for lesion size and location and for radiation dose. 相似文献
66.
Thanks to improvements in treatment regimens, more and more patients are now surviving cancer. However, cancer survivors are faced with the serious long-term effects of the different modalities of cancer treatments. One of these adverse effects is chemotherapy-induced irreversible damage to the ovarian tissues, which leads to premature ovarian failure and its resulting consequences such as hot flashes, osteoporosis, sexual dysfunction and the risk of infertility. Chemotherapy-induced ovarian failure (or chemotherapy-induced premature menopause) affects the quality of life of female cancer survivors. Although there is no clear definition of chemotherapy-induced ovarian failure, irreversible amenorrhoea lasting for several months (>12 months) following chemotherapy and a follicle stimulating hormone level of > or = 30 MIU/mL in the presence of a negative pregnancy test seems to be an appropriate characterisation. Different chemotherapy agents, alkylating cytotoxics in particular, have the potential to cause progressive and irreversible damage to the ovaries. The result of this damage is a state of premature ovarian failure, with progressive declining of estrogen levels, decreasing bone mass and an increased risk of fractures. Historically, hormonal replacement therapy (HRT) has been used to treat menopausal problems in the general population, but concerns about the potential of estrogen to increase the risk of breast cancer in women at high-risk or increase the risk of recurrence in cancer survivors, have forced physicians to utilise alternative treatments. This review discusses some of the newer therapies that are now available to provide appropriate symptom control, avoid complications such as fractures and possibly prevent infertility by making the ovarian epithelium less susceptible to cytotoxic agents. 相似文献
67.
Olivia Fletcher Lorna Gibson Nichola Johnson Dan R Altmann Jeffrey M P Holly Alan Ashworth Julian Peto Isabel Dos Santos Silva 《Cancer epidemiology, biomarkers & prevention》2005,14(1):2-19
We reviewed all English-language articles on associations among circulating levels of the insulin-like growth factors (IGF) and their binding proteins (IGFBP), polymorphisms in their genes, and breast cancer risk. In premenopausal women, five of eight IGF-I studies and four of six IGFBP-3 studies of circulating levels found that women in the highest quantile had more than twice the risk of developing breast cancer of those in the lowest, although in some this effect was only apparent at young ages. In postmenopausal women, however, there was no consistent effect. A simple sequence length polymorphism 1 kb 5' to IGF-I was examined in relation to circulating levels of IGF-I (12 studies) or breast cancer risk (4 studies), but there was no convincing evidence of any effect. For an A/C polymorphism 5' to IGFBP-3, all three studies were consistent with a modest effect on circulating levels, but no evidence of a direct effect on breast cancer risk was seen in the only relevant study. Variation within the reference range of IGF-I and IGFBP-3 may confer only modest increases in breast cancer risk, and any single polymorphism may only account for a small proportion of that variation. Nevertheless, population attributable fractions for high circulating levels of IGF-I and IGFBP-3 and for common genetic variants could be substantial. Further large studies, or combined analysis of data from existing studies, are needed to quantify these effects more precisely. 相似文献
68.
Eleftherios P Mamounas Ann Brown Stewart Anderson Roy Smith Thomas Julian Barbara Miller Harry D Bear Christopher B Caldwell Alonzo P Walker Wendy M Mikkelson Jay S Stauffer Andre Robidoux Heather Theoret Atilla Soran Atilla Sovan Bernard Fisher D Lawrence Wickerham Norman Wolmark 《Journal of clinical oncology》2005,23(12):2694-2702
PURPOSE: Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: During the conduct of National Surgical Adjuvant Breast and Bowel Project trial B-27, several participating surgeons attempted SNB before the required axillary dissection in 428 patients. All underwent lymphatic mapping and an attempt to identify and remove a sentinel node. Lymphatic mapping was performed with radioactive colloid (14.7%), with lymphazurin blue dye alone (29.9%), or with both (54.7%). RESULTS: Success rate for the identification and removal of a sentinel node was 84.8%. Success rate increased significantly with the use of radioisotope (87.6% to 88.9%) versus with the use of lymphazurin alone (78.1%, P = .03). There were no significant differences in success rate according to clinical tumor size, clinical nodal status, age, or calendar year of random assignment. Of 343 patients who had SNB and axillary dissection, the sentinel nodes were positive in 125 patients and were the only positive nodes in 70 patients (56.0%). Of the 218 patients with negative sentinel nodes, nonsentinel nodes were positive in 15 (false-negative rate, 10.7%; 15 of 140 patients). There were no significant differences in false-negative rate according to clinical patient and tumor characteristics, method of lymphatic mapping, or breast tumor response to chemotherapy. CONCLUSION: These results are comparable to those obtained from multicenter studies evaluating SNB before systemic therapy and suggest that the sentinel node concept is applicable following neoadjuvant chemotherapy. 相似文献
69.
70.